m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05805
|
[1] | |||
m6A modification
MIRLET7E
MIRLET7E
METTL3
Methylation
 : m6A sites
Direct
Enhancement
Non-coding RNA
MIRLET7E
THBS1
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | MIRLET7E | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | MIRLET7E | microRNA | View Details | ||
| Regulated Target | Thrombospondin 1 (THBS1) | View Details | |||
| Crosstalk Relationship | m6A → ncRNA | Enhancement | |||
| Crosstalk Mechanism | m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA | ||||
| Crosstalk Summary | The overexpression of METTL3 increased the levels of both MIRLET7E and individual miRNAs of the miR-17-92 cluster while reducing the expression of Thrombospondin 1 (THBS1). | ||||
| Cell Process | Cell proliferation | ||||
| Cell migration | |||||
In-vitro Model |
HUVEC-C | Normal | Homo sapiens | CVCL_2959 | |
| In-vivo Model | HUVEC were infected with LV-METTL3-shRNA or LV-CT-shRNA particles, as mentioned above. Cells (3×105) were resuspended in 100 μL of medium without FBS and mixed with growth factor reduced matrigel premixed with VEGF (vascular endothelial growth factor)-A165 and bFGF (basic fibroblast growth factor). Samples were injected subcutaneously into the flank region of 10-week-old immunodeficient male mice (Crl:CD1-Foxn1nu, Charles River, United Kingdom; N=8 mice per group) | ||||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| Thrombospondin 1 (THBS1) | 2 Compound(s) Regulating the Target | Click to Show/Hide the Full List | ||
 Compound Name |
ABT-510 | Phase 2 | [2] | |
|---|---|---|---|---|
| Synonyms |
N-Acetyl-N-methyl-glycyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-argininyl-L-proline N-ethylamide
Click to Show/Hide
|
|||
| MOA | Modulator | |||
| External Link | ||||
| Compound Name |
CVX-045 | Phase 2 | [3] | |
| Synonyms |
CVX-22; CovX-045; PF-4856882; TSP-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), Pfizer
Click to Show/Hide
|
|||
| MOA | Agonist | |||
| External Link | ||||
References